Opioid-class REMS unlikely to halt abuse; U.S. trade office IDs Brazil, China, India among counterfeit hot spots;

> Opioid REMS implementation costs will be passed along to consumers and third-party payers, despite their "unlikely" ability to reduce or mitigate opioid abuse. Article

> The Office of the United States Trade Representative cites Brazil, China, India, Indonesia and Russia as areas of concern for the proliferation of counterfeit drugs. Article

> Catalent has named Barry Russell president of its commercial packaging group. Release

> Big-three drug distributor McKesson's yearly outlook beat Wall Street's estimate. Item

> Increasing challenges balanced by sound fundamentals and healthy growth prospects will yield stable credit risk profiles for Indian pharma companies in the international markets, says CRISIL Ratings. Article